Calgary’s MacuMira Launches Breakthrough Device for Vision Loss

When Calgary entrepreneur Justin Sather learned of a promising treatment for dry age-related macular degeneration (dry AMD)—the leading cause of vision loss among adults in Canada—he felt compelled to take action. This inspiration stemmed from his grandmother’s struggles with the condition. Sather explored a German concept that had yet to be commercialized, leading to the establishment of MacuMira Medical Devices. After nearly seven years of development, testing, and obtaining approval from Health Canada, Sather’s retinal microcurrent stimulation device is now available nationwide.

“This represents a turning point in care for patients with dry AMD,” said Sather, who serves as the CEO of MacuMira. “Losing your driver’s licence, struggling to read, or not being able to apply makeup or recognize your grandchildren are daily realities for many Canadians with this disease. With MacuMira, we are restoring independence, dignity, and the ability to fully participate in life’s moments.”

Dry AMD affects over two million Canadians, causing blurred vision and gradual loss of central vision. Historically, patients diagnosed with this condition faced limited options, often resigned to the prospect of progressive vision loss, which posed significant challenges for both patients and healthcare providers.

MacuMira’s system employs low-dose microcurrent stimulation delivered through closed eyelids in 32-minute sessions. This non-invasive, painless treatment is administered via specialized headsets, allowing patients to return home immediately after the procedure. The technology aims to stimulate retinal cells, enhancing mitochondrial function, reducing inflammation, and increasing ATP production.

A randomized controlled trial published in the International Journal of Retina and Vitreous highlighted substantial improvements in visual acuity and contrast sensitivity among patients, with no adverse events linked to the device. “It’s encouraging to see that new technologies are being developed and offered to patients in Canada with dry age-related macular degeneration who previously had little hope for improvement,” stated Dr. Amit Gupta, an ophthalmologist and retina specialist at Clarity Eye Institute in Toronto.

With a commitment to redefining the management of dry AMD globally, MacuMira has provided more than 15,000 treatments across Canada, available exclusively through eye-care professionals. As the company continues to innovate, it aims to offer renewed hope to those affected by this debilitating condition, transforming the landscape of vision care in Canada and beyond.